-
1Academic Journal
Authors: L. F. Stovba, N. K. Chernikova, A. L. Khmelev, S. V. Borisevich, Л. Ф. Стовба, Н. К. Черникова, А. Л. Хмелев, С. В. Борисевич
Source: Problems of Particularly Dangerous Infections; № 1 (2025); 105-111 ; Проблемы особо опасных инфекций; № 1 (2025); 105-111 ; 2658-719X ; 0370-1069
Subject Terms: клеточный иммунитет, orthopoxviruses, anti-vector immunity, clinical trials, immunodominant antigens, antibodies, cellular immunity, ортопоксвирусы, антивекторный иммунитет, клинические испытания, иммунодоминантные антигены, антитела
File Description: application/pdf
Relation: https://journal.microbe.ru/jour/article/view/2121/1549; Silva N.I.O., de Oliveira J.S., Kroon E.G., Trindade G.S., Drumond B.P. Here, there, and everywhere: The wide host range and geographic distribution of zoonotic orthopoxviruses. Viruses. 2020; 13(1):43. DOI:10.3390/v13010043.; Gao J., Gigante C., Khmaladze E., Liu P., Tang S., Wilkins K., Zhao K., Davidson W., Nakazawa Y., Maghlakelidze G., Geleishvili M., Kokhreidze M., Carroll D.S., Emerson G., Li Y. Genome sequences of Akhmeta virus, an early divergent old world orthopoxvirus. Viruses. 2018; 10(5):252. DOI:10.3390/v10050252.; Cardetti G., Gruber C.E.M., Eleni C., Carletti F., Castilletti C., Manna G., Rosone F., Giombini E., Selleri M., Lapa D., Puro V., Di Caro A., Lorenzetti R., Scicluna M.T., Grifoni G., Rizzoli A., Tagliapietra V., De Marco L., Capobianchi M.R., Autorino G.L. Fatal outbreak in Tonkean macaques cause by possible novel orthopoxvirus, Italy, January 2015. Emerg. Infect. Dis. 2017; 23(12):1941–9. DOI:10.3201/eid2312.162098.; Gruber C.E.M., Giombini E., Selleri M., Tausch S.H., Andrusch A., Tyshaieva A., Cardeti G., Lorenzetti R., De Marco L., Carletti F., Nitsche A., Capobianchi M.R., Ippolito G., Autorino G.L., Castilletti C. Whole genome characterization of orthopoxvirus (OPV) Abatino, a zoonotic virus representing a putative novel clade of old world orthopoxvirus. Viruses. 2018; 10(10):546. DOI:10.3390/v10100546.; Gigante C.M., Gao J., Tang S., McCollum A.M., Wilkins K., Reynolds M.G., Davidson W., McLaughlin J., Olson V.A., Li Y. Genome of Alaskapox virus, a novel orthopoxvirus isolated from Alaska. Viruses. 2019; 11(8):708. DOI:10.3390/v11080708.; Gorse G.J., Newman M.J., deCamp A., Hay C.M., De Rosa S.C., Noonan E., Livingston B.D., Fuchs J.D., Kalams S.A., CassisGhavami F.L.; NIAID HIV Vaccine Trials Network. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin. Vaccine Immunol. 2012; 19(5):649–58. DOI:10.1128/CVI.00038-12.; Vasan S., Schlesinger S.J., Chen Z., Hurley A., Lombardo A., Than S., Adesanya P., Bunce C., Boaz M., Boyle R., Sayeed E., Clark L., Dugin D., Boente-Carrera M., Schmidt C., Fang Q., LeiBa, Huang Y., Zaharatos G.J., Gardiner D.F., Caskey M., Seamons L., Ho M., Dally L., Smith C., Cox J., Gill D., Gilmour J., Keefer M.C., Fast P., Ho D.D. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1B'/C candidate vaccine. PLoS One. 2010; 5(1):e8816. DOI:10.1371/journal. pone.0008816.; Walsh S.R., Seaman M.S., Grandpre L.E. Charbonneau C., Yanosick K.E., Metch B., Keefer M.C., Dolin R., Baden L.R. Impact of anti-orthopoxvirus neutralizing antibodies induced by heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. Vaccine. 2012; 31(1):114–9. DOI:10.1016/jvaccine.2012.10.093.; Sandström E., Nilsson C., Hejdeman B., Bråve A., Bratt G., Robb M., Cox J., Vancott T., Marovich M., Stout R., Aboud S., Bakari M., Pallangyo K., Ljungberg K., Moss B., Earl P., Michael N., Birx D., Mhalu F., Wahren B., Biberfeld G.; HIV Immunogenicity Study 01/02 Team. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 2008; 198(10):1482– 90. DOI:10.1086/592507.; Nilsson C., Godoy-Ramirez K., Hejdeman B., Bråve A., Gudmundsdotter L., Hallengärd D., Currier J.R., Wieczorek L., Hasselrot K., Earl P.L., Polonis V.R., Marovich M.A., Robb M.L., Sandström E., Wahren B., Biberfeld G. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus Ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. AIDS Res. Hum. Retroviruses. 2014; 30(3):299–311. DOI:10.1089/AID.2013.0149.; García F., Bernaldo de Quirós J.C.L., Gómez C.E., Perdiguero B., Nájera J.L., Jiménez V., García-Arriaza J., Guardo A.C., Pérez I., Díaz-Brito V., Conde M.S., González N., Alvarez A., Alcamí J., Jiménez J.L., Pich J., Arnaiz J.A., Maleno M.J., León A., Muñoz-Fernández M.A., Liljeström P., Weber J., Pantaleo G., Gatell J.M., Plana M., Esteban M. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine. 2011; 29(46):8309–16. DOI:10.1016/j.vaccine.2011.08.098.; Guardo A.C., Gómez C.E., Díaz-Brito V., Pich J., Arnaiz J.A., Perdiguero B., García-Arriaza J., González N., Sorzano C.O.S., Jiménez L., Jiménez J.L., Muñoz-Fernández M.Á., Gatell J.M., Alcamí J., Esteban M., de Quirós J.C.L.B., García F., Plana M.; RISVAC02boost study. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS One. 2017; 12(10):e0186602. DOI:10.1371/journal.pone.0186602.; Mehendаle S., Thakar M., Sahay S., Kumar M., Shete A., Sathyamurthi P., Verma A., Kurle S., Shrotri A., Gilmour J., Goyal R., Dally L., Sayeed E., Zachariah D., Ackland J., Kochhar S., Cox J.H., Excler J.-L., Kumaraswami V., Paranjape R., Ramanathan V.D. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised trial in HIVuninfected Indian volunteers. PLoS One. 2013; 8(2):e55831. DOI:10.1371/journal.pone.0055831.; Hayes P., Gilmour J., von Lieven A., Gill D., Clark L., Kopycinski J., Cheeseman H., Chung A., Alter G., Dally L., Zachariah D., Lombardo A., Ackland J., Sayeed E., Jackson A., Boffito M., Gazzard B., Fast P.E., Cox J.H., Laufer D. Safety and immunogenicity of DNA prime and modified vaccinia Ankara virus-HIV sub-type C vaccine boost in healthy adults. Clin. Vaccine Immunol. 2013; 20(3):397–408. DOI:10.1128/CVI.00637-12.; Gómez C.E., Perdiguero B., García-Arriaza J., Cepeda V., Sánchez-Sorzano C.Ó., Mothe B., Jiménez J. L., Muñoz-Fernández M.Á., Gatell J.M., López Bernaldo de Quirós J.C., Brander C., García F., Esteban M. A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART. PLoS One. 2015; 10(11):e0141456. DOI:10.1371/journal.pone.0141456.; Goepfert P.A., Elizaga M.L., Sato A., Qin L., Cardinali M., Hay C.M., Hural J., DeRosa S.C., DeFawe O.D., Tomaras G.D., Montefiori D.C., Xu Y., Lai L., Kalams S.A., Baden L.R., Frey S.E., Blattner W.A., Wyatt L.S., Moss B., Robinson H.L.; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis. 2011; 203(5):610–9. DOI:10.1093/infdis/jiq105.; Satti I., Meyer J., Harris S.A., Manjaly Thomas Z.-R., Griffiths K., Antrobus R.D., Rowland R., Ramon R.L., Smith M., Sheehan S., Bettinson H., McShane H. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomized controlled trial. Lancet. Infect. Dis. 2014; 14(10):939–46. DOI:10.1016/S1473-3099(14)70845-X.; von Krempelhuber A., Vollmar J., Pokorny R., Rapp P., Wulff N., Petzold B., Handley A., Mateo L., Siersbol H., Kollaritsch H., Chaplin P. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®. Vaccine. 2010; 28(5):1209–16. DOI:10.1016/j.vaccine.2009.11.030.; Frey S.E., Winokur P.L., Hill H., Goll J.B., Chaplin P., Belshe R.B. Phase II randomized, double-blinded comparison of a single high dose (5·108 TCID50) of modified vaccinia Ankara compared to a standard dose (1·108 TCID50) in healthy vaccinianaïve individuals. Vaccine. 2014; 32(23):2732–9. DOI: 10/1016/j. vaccine.2014.02.043.; Greenberg R.N., Hay C.M., Stapleton J.T., Marbury T.C., Wagner E., Kreitmeir E., Röesch S., von Krempelhuber A., Young P., Nichols R., Meyer T.P., Schmidt D., Weigl J., Virgin G., ArndtzWiedemann N., Chaplin P. A randomized, double-blind, placebo controlled Phase II trial investigating the safety and immunogeni city of modified vaccinia Ankara smallpox vaccine (MVA-BN®) in 56-80-year-old subjects. PLoS One. 2016; 11(6):e0157335. DOI:10.1371/journal.pone.0157335.; https://journal.microbe.ru/jour/article/view/2121
-
2Academic Journal
Authors: L. F. Stovba, O. V. Chukhralya, D. I. Pavel’ev, N. K. Chernikova, S. V. Borisevich, Л. Ф. Стовба, О. В. Чухраля, Д. И. Павельев, Н. К. Черникова, С. В. Борисевич
Source: Problems of Particularly Dangerous Infections; № 4 (2023); 24-31 ; Проблемы особо опасных инфекций; № 4 (2023); 24-31 ; 2658-719X ; 0370-1069
Subject Terms: мультивалентные вакцины, MVA strain, Ebola fever, immunization, priming, booster dose, immunodominant antigens, multivalent vaccines, штамм MVA, лихорадка Эбола, иммунизация, праймирование, бустирование, иммунодоминантные антигены
File Description: application/pdf
Relation: https://journal.microbe.ru/jour/article/view/1893/1428; [Corporate Author]. Ebola haemorrhagic fever in Zaire, 1976. Report of an International Commission. Bull. World Health Organ. 1978; 56(2):271–93.; Leroy E.M., Kumulungui B., Pourrut X., Rouquet P., Hassanin A., Yaba P., Délicat A., Paweska J.T., Gonzalez J.P., Swanepoel R. Fruit bats as reservoirs of Ebola virus. Nature. 2005; 438(7068):575–6. DOI:10.1038/438575a.; World Health Organization. Ebola Virus Disease. Situation Report. 26 May 2016. Available from: http://apps.who.int/iris/bitstream/10665/206924/1/ebolasitrep26May2016eng.pdf?ua=1.; Wong G., Mendoza E.J., Plummer F.A., Gao G.F., Kobinger G.P., Qiu X. From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin. Biol. Ther. 2018; 18(2):159–73. DOI:10.1080/14712598.1018.1404572.; Dolzhikova I.V., Tokarskaya E.A., Dzharullaeva A.S., Tukhvatulin A.I., Shcheblyakov D.V., Voronina O.L., Syromyatnikova S.I., Borisevich S.V., Pantyukhov V.B., Babira V.F., Kolobukhina L.V., Naroditsky B.S., Logunov D.Y., Gintsburg A.L. Virus-vectored Ebola vaccines. Acta Naturae. 2017; 9(3):4–11.; Sridhar S. Clinical development of Ebola vaccines. Ther. Adv. Vaccines. 2015; 3(5-6):125–38. DOI:10.1177/2051013615611017.; Frey S.E., Winokur P.L., Salata R.A., EL-Kamary S.S., Turley C.B., Walter E.B. Jr, Hay C.M., Newman F.K., Hill H.R., Zhang Y., Chaplin P., Tary-Lehmann M., Belshe R.B. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. Vaccine. 2013; 31(29):3025–33. DOI:10.1016/j.vaccine.2013.04.050.; Ndiaye B.P., Thieneman F., Ota M., Landry B.S., Camara M., Dieye S. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomized, placebo-controlled, phase 2 trial. Lancet. Respir. Med. 2015; 3(3):190–200. DOI:10.1016/S2213-2600(15)00037-5.; Greenberg R.N., Hay C.M., Stapleton J.T., Marbury T.C., Wagner E., Kreitmeir E., Röesch., von Krempelhuber A., Young P., Nichols R., Meuer T.P., Schmidt D., Weigl J., Virgin G., Arndtz-Wiedemann N., Chaplin P. A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of modified vaccinia Ankara smallpox vaccine (MVA-BN®) in 56–80-year-old subjects. PloS One. 2016; 11(6):e0157335. DOI: 10/1371/journal.pone.0157335.; Greenberg R.N., Hurley M.Y., Dinh V.D., Mraz S., Vera J.G., von Bredow D., von Krempelhuber A., Roesch S., Virgin G., Arndtz-Wiedemann N., Meyer T.P., Schmidt D., Nichols R., Young P., Chaplin P. A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA small-pox vaccine (IMVAMUNE) in 18–40 year old subjects with diagnosed atopic dermatitis. PloS One. 2015; 10(10):e0138348. DOI: 10/1371/journal.pone.0138348.; Greenberg R.N., Overton E.T., Haas D.W., Frank I., Goldman M., von Krempelhuber A., Virgin G., Bädeker N., Vollmar J., Chaplin P. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J. Infect. Dis. 2013; 207(5):749–58. DOI:10.1093/infdis/jis753.; Overton E.T., Stapleton J., Frank I., Haasler S., Goepfert P.A., Barker D., Wagner E., von Krempelhuber A., Virgin G., Meyer T.P., Müller J., Bädeker N., Grünert R., Young P., Rösch S., Maclennan J., Arndtz-Wiedemann N., Chaplin P. Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: An open-label, controlled clinical phase II trial. Open Forum Infect. Dis. 2015; 2(2):ofv040. DOI: 10/1093/ofid/ofv040.; Zitzman-Roth E.-M., von Sonnenburg F., de la Motte S., Arndtz-Wiedemann N., von Krempelhuber A., Uebler N., Vollmar J., Virgin G., Chaplin P. Cardiac safety of modified vaccinia Ankara for vaccination against smallpox in a young, healthy study population. PloS One. 2015; 10(4):e0122653. DOI:10.1371//journal.pone.0122653.; Lázaro-Frías A., Gómez-Medina S., Sánchez-Sampedro L., Ljungberg K., Ustav M., Liljeström P., Muñoz-Fontela C., Esteban M., García-Arriaza J. Distinct immunogenicity and efficacy of pox-virus-based vaccine candidates against Ebola virus expressing GP and VP40 proteins. J. Virol. 2018; 92(11):e00363-18. DOI:10.1128/JVI.00363-18.; Domi A., Feldman F., Basu R., McCurley N., Shifflett K., Emanuel J., Hellerstein M.S., Guirakhoo F., Orlandi C., Flinko R., Lewis G.K., Hanley P.W., Feldmann H., Robinson H.L., Marzi A. A single dose of modified vaccinia Ankara expressing Ebola virus like particles protects nonhuman primates from lethal Ebola virus challenge. Sci. Rep. 2018; 8(1):864. DOI:10.1038/s41598-017-19041-y.; Schweneker M., Laimbacher A.S., Zimmer G., Wagner S., Schraner E.M., Wolferstätter M., Klingenberg M., Dirmeier U., Steigerwald R., Lauterbach H., Hochrein H., Chaplin P., Suter M., Hausmann J. Recombinant modified vaccinia virus Ankara geeing Ebola virus-like particles. J. Virol. 2017; 91(11):e00343-17. DOI:10.1128/JVI.00343-17.; Callendret B., Vellinga J., Wunderlich K., Rodrigues A., Steigerward R., Dirmeier U., Cheminay C., Volkmann A., Brasel T., Carrion R., Giavedoni L.D., Patterson J.L., Mire C.E., Geisbert T.W., Hooper J.W., Weijtens M., Hartkoorn-Pasma J., Custers J., Grazia Pau M., Schuitemaker H., Zahn R. A prophylactic multivalent vaccine against different filovirus species is immunogenetic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PloS One. 2018; 13(2):e0192312. DOI:10.1371/journal.pone.0192312.; Hensley L.E., Mulangu S., Asiedu C., Johnson J., Honko A.N., Stanley D., Fabozzi G., Nichol S.T., Ksiazek T.G., Rollin P.E., Wahl-Jensen V., Bailey M., Jahrling P.B., Roederer M., Koup R.A., Sullivan N.J. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PloS Pathog. 2010; 6(5):e1000904. DOI:10.1371/journal.ppat.1000904.; Tapia M.D., Sow S.O., Lyke K.E., Haidara F.C., Diallo F., Doumbia M., Traore A., Coulibaly F., Kodio M., Onwuchekwa U., Sztein M.B., Wahid R., Campbell J.D., Kieny M.P., Moorthy V., Imoukhuede E.B., Rampling T., Roman F., De Ryck I., Bellamy A.R., Dally L., Mbaya O.T., Ploquin A., Zhou Y., Stanley D.A., Bailer R., Koup R.A., Roederer M., Ledgerwood J., Hill A.V.S., Ballou W.R., Sullivan N., Graham B., Levine M.M. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet. Infect. Dis. 2016; 16(1):31–42. DOI:10.1016/S1473-3099(15)00362-X.; Stanley D.A., Honko A.N., Asiedu C., Trefry J.C., Lau-Kilby A.W., Johnson J.C., Hensley L., Ammendola V., Abbate A., Grazioli F., Foulds K.E., Cheng C., Wang L., Donaldson M.M., Colloca S., Folgori A., Roederer M., Nabel G.J., Mascola J., Nicosia A., Cortese R., Koup R.A., Sullivan N.J. Chimpanzee adenovirus vaccine generates acuate and durable protective immunity against Ebolavirus challenge. Nat. Med. 2014; 20(10):1126–29. DOI:10.1038/nm.3702.; Plotkin S.A., Gilbert P.B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 2012; 54(11):1615–7. DOI:10.1093/cid/cis238.; Venkatraman N., Ndiaye B.P., Bowyer G., Wade D., Sridhar S., Wright D., Powlson J., Ndiaye I., Dièye S., Thompson C., Bakhoum M., Morter R., Capone S., Del Sorbo M., Jamieson S., Rampling T., Datoo M., Roberts R., Poulton I., Griffiths O., Ballou W.R., Roman F., Lewis D.J.M., Lawrie A., Imoukhuede E., Gilbert S.C., Dieye T.N., Ewer K.J., Mboup S., Hill A.V.S. Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal. J. Infect. Dis. 2019; 219(8):1187–97. DOI:10.1093/infdis/jiy639.; Dahlke C., Lunemann S., Kasonta R., Kreuels B., Schmiedel S., Ly M.L., Fehling S.K., Strecker T., Becker S., Altfeld M., Sow A., Lohse A.W., Muñoz-Fontela C., Addo M.M. Comprehensive characterization of cellular immune responses following Ebola virus infection. J. Infect. Dis. 2017; 215(2):287–92. DOI:10.1093/infdis/jiw508.; Milligan I.D., Gibani M.M., Sewell R., Clutterbuck E.A., Campbell D., Plested E., Nuthall E., Voysey M., Silva-Reyes L., McElrath M.J., De Rosa S.C., Frahm N., Cohen K.W., Shukarev G., Orzabal N., van Duijnhoven W., Truyers C., Bachmayer N., Splinter D., Samy N., Pau M.G., Schuitemaker H., Luhn K., Callendret B., Van Hoof J., Douoguih M., Ewer K., Angus B., Pollard A.J., Snape M.D. Safety and immunogenicity of novel adenovirus type 26 – and modified vaccinia Ankara – vectored Ebola vaccine: A randomized clinical trial. JAMA. 2016; 315(15):1610–23. DOI:10.1001jama.2016.4218.; Coltart C.E.M., Johnson A.M., Whitty C.J.M. Role of healthcare workers in early epidemic spread of Ebola: policy implication of prophylactic compared to reactive vaccination policy in outbreak prevention and control. BMC Med. 2015; 13:271. DOI:10.1186/s12916-015-0477-2.; https://journal.microbe.ru/jour/article/view/1893